---
title: "China Meheco's subsidiary has passed the consistency evaluation of the generic drug Lincomycin Hydrochloride Injection"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258476100.md"
description: "China Meheco's wholly-owned subsidiary Tianfang Pharmaceutical recently received approval from the National Medical Products Administration, with its Lincomycin Hydrochloride Injection passing the consistency evaluation for generic drugs. This medication is primarily used to treat severe infections caused by sensitive strains of bacteria. After passing the consistency evaluation, this drug will receive greater support in areas such as medical insurance payments and procurement by medical institutions, helping to enhance market competitiveness and expand market share"
datetime: "2025-09-23T08:12:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258476100.md)
  - [en](https://longbridge.com/en/news/258476100.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258476100.md)
---

# China Meheco's subsidiary has passed the consistency evaluation of the generic drug Lincomycin Hydrochloride Injection

According to the announcement from China Meheco (600056.SH), its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. (referred to as "Tianfang Pharmaceutical") has recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration (referred to as "NMPA") for Lincomycin Hydrochloride Injection. This drug has passed the consistency evaluation of generic drug quality and efficacy.

Lincomycin Hydrochloride Injection is mainly used to treat severe infections caused by sensitive strains such as Streptococcus, Pneumococcus, and Staphylococcus. According to relevant national policies, drug varieties that pass the consistency evaluation will receive greater support in areas such as medical insurance payments and medical institution procurement. The passing of the consistency evaluation for Tianfang Pharmaceutical's Lincomycin Hydrochloride Injection will help enhance the market competitiveness of this drug and further expand its market share

### Related Stocks

- [600056.CN](https://longbridge.com/en/quote/600056.CN.md)

## Related News & Research

- [China Telecom's Shares Rise After Becoming Last of Country's Big Three Telcos to Roll Out Token Plans](https://longbridge.com/en/news/286859736.md)
- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [16:51 ETBeverly Hills MD ProRetinol Age Rewind x3 Officially Launches: A New Era of Gentle, Slow-Released Retinol Skincare Backed by Plastic Surgeons](https://longbridge.com/en/news/286966075.md)